We need a common regulator for pharma sector: FICCI chairman

We need a common regulator for pharma sector: FICCI chairman

The pharmaceuticals and medical devices sector, which is currently governed by multiple regulators and ministries, needs a common regulator to simplify processes, said Federation of Indian Chambers of Commerce and Industry (FICCI) chairman here.

Speaking at the sidelines of a seminar at the Vibrant Gujarat Global Summit here, Pankaj Patel, chairman and managing director of Cadila Healthcare and said that there was a need to simplify the regulatory processes governing the pharmaceutical sector.

“A common regulator for the entire sector covering drugs, medical devices and others would simplify the processes and improve ease of doing business,” Patel who is also the chairman of FICCI said.

He added that now there were multiple regulators including the National Pharmaceutical Pricing Authority (NPPA), the Central Drugs Standard Control Organisation (CDSCO) and others which come under the purview of various ministries.

The NPPA which comes under the Department of Pharmaceuticals, Ministry of chemicals and fertilisers looks after drug pricing in the country and comes out with directives on the same. The CDSCO, in turn, has regulatory control over the import of drugs, approval of new drugs, clinical trials, among several others. It comes under the ministry of health and family welfare.

Mansukh L Mandaviya, minister of state for chemicals and fertilisers, said that it was too early to comment on such a recommendation.

Federation of Indian Chambers of Commerce & Industry

Established in 1927, FICCI is the largest and oldest apex business organisation in India. Its history is closely interwoven with India’s struggle for independence, its industrialization, and its emergence as one of the most rapidly growing global economies.

A non-government, not-for-profit organisation, FICCI is the voice of India’s business and industry. From influencing policy to encouraging debate, engaging with policy makers and civil society, FICCI articulates the views and concerns of industry. It serves its members from the Indian private and public corporate sectors and multinational companies, drawing its strength from diverse regional chambers of commerce and industry across states, reaching out to over 2,50,000 companies.

FICCI provides a platform for networking and consensus building within and across sectors and is the first port of call for Indian industry, policy makers and the international business community.

Mansukh L Mandaviya, minister of state for chemicals and fertilisers, said that it was too early to comment on such a recommendation.

About Taj Pharma

Taj Pharmaceuticals is the global leader in generics and one of the India’s top ten pharmaceutical companies. Taj Pharma India play a leading role in therapeutic areas such as cancer, virology and transplantation. The combined strengths of Taj Pharma generics and pharmaceuticals businesses, coupled with expertise in the emerging genetic sciences, equip us to develop integrated healthcare solutions and therapeutic approaches tailored to individual patients’ needs. Taj Pharmaceutical’s products and services address the entire healthcare spectrum, from screening for genetic risk factors, to preventing, diagnosing and treating disease, and monitoring the treatment response.

Taj Pharma India delivers a unique contribution to better healthcare. Taj Pharma India aim to reduce suffering and improve health and quality of life of people all around the world. At Taj Pharmaceuticals, Taj Pharma India have pursued this mission with patience, dedication, imagination and skill, for over a century. Taj Pharma vision is to develop targeted medicines and diagnostic tools that combine to offer patients, physicians and payers better, safer, more cost-effective healthcare.

Once again, welcome to Taj Pharmaceuticals, a great company that is translating a great vision into reality – We Innovate Healthcare.